With a multibillion dollar investment from Microsoft and already 4 authorship credits on PubMed, ChatGPT is poised to disrupt Medical Affairs.
2023 brings increased expectations from the FDA for patient-focused drug development (PFDD). Medical Affairs organizations need to develop new skills to put the patient voice at the center of drug, device, and diagnostic development and evaluation.
Library of video interviews with Medical Affairs leaders discussing the future of the function, building Medical from scratch, the Medical professional, and much more.
Based on discussions between 80 cross-industry Field Medical colleagues from small to large biopharmaceutical and medtech companies, this article highlights key actions for Medical Affairs teams to consider for implementation in their own organizations.
MAPS speaks with Eric Peacock, co-Founder and CEO of MyHealthTeam, about the alignment between social justice and business best-practices to promote health equity using patient communities.
This Altmetric White Paper explores how to measure the value of Medical Affairs publications beyond counting citations.
This article outlines the aspects of Medical Affairs strategy and launch excellence specific to supporting the development and launch of treatments targeting rare diseases, providing a roadmap for MA teams and organizations undertaking this planning.
The Medical Affairs Professional Society (MAPS) and the Industry Pharmacists Organization (IPhO) are pleased to announce an important new strategic collaboration to help advance the careers of student pharmacists interested in the pharmaceutical industry, as well as Fellows and early-stage Industry Pharmacist professionals.
MAPS speaks with Sameer Lal, SVP, Enterprise Medical Business Unit, Indegene about how to move from today’s largely siloed customer engagement framework to a truly cross-functional, omnichannel approach.
Instead of being static representations of an event, insights can become actionable—informing what can be done to improve future events or even larger business decisions.